Company: PRGO
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001585364-25-000056
Chunk: 59

Company: PERRIGO Co plc
Filing Date: 2025-05-07
Form: 10-Q
Item: Item 1
Chunk 59
---
4 1.3 %Oral Care22.5 28.7 (6.2)(21.6)%Digestive Health9.6 9.5 0.1 1.1 %Other CSCI15.9 23.3 (7.4)(31.8)%Total CSCI$423.1 $437.9 $(14.8)(3.4)%

Sales in each category were driven primarily by: 

•Skin Care: Net sales of $111.5 million decreased 2.8%, inclusive of a 3.4% unfavorable effect of currency translation, including the impact of -1.8% from divested businesses and exited product lines. Growth was led by brands Compeed® and Sebamed®, and earlier customer purchases ahead of the spring/summer season compared to the prior year.  

•Upper Respiratory: Net sales of $73.5 million increased 6.4%, inclusive of a 2.7% unfavorable effect of currency translation, due primarily to higher cough cold seasonal sell-in activities, improved supply of a key product and slightly higher incidence levels of cough cold compared to the prior year quarter. In addition, growth in allergy products, including Beconase® and store brand allergy offerings, also added to growth.   

•Healthy Lifestyle: Net sales of $66.6 million increased 3.1%, inclusive of a 4.5% unfavorable effect of currency translation, as strong momentum behind smoking cessation brand NiQuitin® were more than offset by lower category consumption in weight loss, impacting XLS Medical®, and parasites. 

•Pain & Sleep-Aids: Net sales of $53.6 million increased 4.3%, inclusive of a 0.9% unfavorable effect of currency translation, as higher net sales of Solpadeine®, due primarily to improved supply, were partially offset by 3.7% from divested businesses and exited product lines. 

•VMS: Net sales of $37.7 million decreased 15.5%, inclusive of a 2.6% unfavorable effect of currency translation, due primarily to deprioritization of the nutraceuticals portfolio. 

•Women's Health: Net sales of $32.4 million increased 1.3%, inclusive of a 2.9% unfavorable effect of currency translation, due primarily to higher net sales of contraceptive products including ellaOne®, driven by market share gains.